A5053679135- Cancer Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Glycosylation and Glycoproteins Research
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Microtubule and mitosis dynamics
- Cancer Immunotherapy and Biomarkers
- Ubiquitin and proteasome pathways
- Immune Cell Function and Interaction
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Genetics, Bioinformatics, and Biomedical Research
- Lymphoma Diagnosis and Treatment
- 3D Printing in Biomedical Research
- Cancer Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Multiple and Secondary Primary Cancers
- Breast Cancer Treatment Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
Institut Pasteur de Tunis
2024-2025
Tunis University
2013-2025
Centre de Recherche en Cancérologie de Marseille
2014-2024
Inserm
2014-2024
Aix-Marseille Université
2016-2024
Tunis El Manar University
2013-2024
Cornell University
2022-2024
Weill Cornell Medicine
2022-2024
Northwestern University
2021-2023
The University of Texas MD Anderson Cancer Center
2023
Abstract Most circulating tumor cells (CTC) are detected as single cells, whereas a small proportion of CTCs in multicellular clusters with stemness properties possess 20- to 100-times higher metastatic propensity than the cells. Here we report that CTC dynamics both singles and response therapies predict overall survival for breast cancer. Chemotherapy-evasive relatively quiescent specific loss ST6GAL1-catalyzed α2,6-sialylation glycoproteins. Dynamic hyposialylation or deficiency ST6GAL1...
Breast cancers (BCs) of the luminal B subtype are estrogen receptor-positive (ER+), highly proliferative, resistant to standard therapies and have a poor prognosis. To better understand this we compared DNA copy number aberrations (CNAs), promoter methylation, gene expression profiles, somatic mutations in nine selected genes, 32 tumors with those observed 156 BCs other molecular subtypes. Frequent CNAs included 8p11-p12 11q13.1-q13.2 amplifications, 7q11.22-q34, 8q21.12-q24.23,...
Background: Multiple sclerosis (MS) is characterized by a combination of inflammatory and demyelination processes in the spinal cord brain. Conventional drugs generally target autoimmune response, without any curative effect. For that reason, there great interest identifying novel agents with anti-inflammatory myelinating effects, to counter inflammation cell death distinctive disease. Methods results: An vitro assay showed curcumin (Cur) at 10 µM enhanced proliferation C8-D1A cells...
// Maroua Manai 1, 5, 6, 7 , Jeanne Thomassin-Piana 2, * Amor Gamoudi Pascal Finetti Marc Lopez 1 Radhia Eghozzi 6 Sinda Ayadi Olfa Ben Lamine Mohamed 5 Khaled Rahal Emmanuelle Charafe-Jauffret 3 Jocelyne Jacquemier 2 Patrice Viens 3, 4 Daniel Birnbaum Hamouda Boussen Max Chaffanet François Bertucci Département d'Oncologie Moléculaire, Centre de Recherche en Cancérologie Marseille, Aix Marseille Université, France Bio-Pathologie, Institut Paoli-Calmettes, UFR Médecine, Médicale, Biologie,...
We recently identified a cell-of-origin-specific mRNA signature associated with metastasis and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin is the over-expression of histone deacetylases zinc finger protein HDAC1, HDAC7, ZNF92, respectively. Based on this signature, we discovered that combination three drugs (an HDAC inhibitor, an anti-helminthic Niclosamide, antibiotic Tanespimycin inhibits HSP90) synergistically reduces proliferation twelve tested cell lines....
Immunotherapy by blocking immune checkpoint regulators has emerged as a new targeted therapy for some cancers. Among them V-domain Ig suppressor of Tcell activation (VISTA) which is identified novel regulator in ovarian cancer. This study aimed to investigate the VISTA role Epithelial cancer (EOC), and its relationship with tumor-infiltrating lymphocytes (TILs) markers prognostic value. The expression VISTA, CD3, CD8, CD4, FOXP3, CD56 was assessed 168 EOC tissue microarrays (TMA)...
Introduction Immunotherapy by blocking immune checkpoints programmed death/ligand (PD1/PDL1) and cytotoxic T-lymphocyte-associated protein 4(CTLA4) has emerged as new therapeutic targets in cancer. However, their efficacy been limited due to resistance. A new- checkpoint V-domain Ig-containing suppressor of T cell activation (VISTA) appeared, but the use its inhibition effect combination with antibodies targeting PDL1/PD1and CTLA4 not reported ovarian Methods In this study, we investigated...
Although the detection of CTCs expressing HER2 at low intensity (HER2-low CTCs) has been shown to have a negative prognostic value in metastatic breast cancer (MBC) patients, biological intrinsic nature HER2-low remains unexplored. Considering technical challenges behind selective collection immunophenotype-specific CTCs, we developed pipeline individually capture CTCs. Four different cell lines (MDA-MB-231, T47D, MDA-MB-453, and SKBR3), that are known express immunohistochemistry levels...
To report epidemiological and anatomo-clinical features within a retrospective series of inflammatory breast cancer to evaluate prognostic factors. This study included 210 Tunisian patients presenting clinically diagnosed IBC, treated at the Institute Salah Azaiez (ISA) Tunis, Tunisia, from 2008 2013. We collected data on epidemiology, biological histologic response neoadjuvant therapy. Overall disease-free survivals were calculated by Kaplan-Meier method compared log-rank tests Cox's models...
Background: Epithelial ovarian cancer (EOC) is the major gynecological cause of deaths. Annexin A1 (ANXA1) protein has been implicated in aggressiveness several types. Materials and Methods: This study retrospectively assessed ANXA1 expression epithelial cells 156 pre-chemotherapy EOC samples 34 normal from patients treated at Salah Azaiez Institute. Using immunohistochemistry, was compared versus samples; correlations with clinicopathological features, including overall survival, were...
Abstract Background: Invasive lobular carcinoma (ILC) has distinctive clinical and molecular features compared with invasive ductal (IDC). CTCs tdEVs are independent prognostic factors in MBC, however, liquid biopsy studies focusing on ILC to date scarce. Higher CTC levels have been observed than IDC. One study including 28 pts suggested the use of higher cutoff for prognosis stratification. The significance is unexplored. This aimed assess differences distribution value between Methods:...
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Identification of new therapeutic targets crucial. MARCKS, myristoylated alanine-rich C-kinase substrate, has been implicated in aggressiveness several cancers and MARCKS inhibitors are development. Using immunohistochemistry (IHC), we retrospectively assessed expression epithelial stromal cells 118 pre-chemotherapy EOC samples 40 normal from patients treated at Salah Azaiez Institute. We compared versus samples,...
Male breast cancer (MBC) is a rare and aggressive disease. Thus, identification of new therapeutic targets crucial.Our objective was to evaluate the protein expression MARCKS (Myristoylated Alanine-Rich C-Kinase Substrate) in MBC investigate its prognostic value.MARCKS tumor stromal cells analyzed by immunohistochemistry (IHC) retrospective series 96 pre-chemotherapy samples 80 normal samples, from Tunisian patients treated at Salah Azaiez Institute. Correlations were searched between...
Inflammatory breast cancer (IBC) is the most pro-metastatic form of (BC). We previously demonstrated that protein overexpression Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) was associated with shorter survival in IBC patients. MARCKS has been PI3K/AKT pathway. inhibitors are development. Our objective to investigate MARCKS, expressed preferentially non-IBC (nIBC), as a novel potential therapeutic target for IBC. The biologic activity MPS, peptide inhibitor, on cell proliferation,...
1093 Background: Circulating tumor cells (CTCs) expressing epithelial markers (EPCAM, cytokeratin (CK)) and lacking CD45 (a leukocyte marker) have been associated with poor outcome in many cancer types. Nonetheless, the presence of both CK (CK+/CD45+), circulating blood patients (pts) also reported, but not widely investigated. Early evidence indicates that dual-positive (DPcells) are hybrids deriving from fusion macrophages. We previously reported it is possible to detect DPcells pts...
Abstract Background: Liquid biopsy provides a real-time assessment of metastatic breast cancer (MBC). Recently, the complementary prognostic value tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) has been reported. We have previously confirmed strong significance CTCs tdEVs in inflammatory (IBC). While previous studies reported association with DNA (ctDNA) alterations MBC, no evidence is available for tdEVs. This study aimed to analyze ctDNA alterations,...
<p>Supplementary Video S10 shows the clustering video of siCD97 transfected ST6KO cells presented in Fig.5E.</p>
<p>Supplementary Video S10 shows the clustering video of siCD97 transfected ST6KO cells presented in Fig.5E.</p>
<p>Supplementary Video S3 shows the clustering video of ST6KO cells presented in Fig.2B.</p>